(5α,8α,9R,10β)-15,16-Epoxycleroda-3,13(16),14-trien-17-al (97457-12-0)
Identification |
Properties |
Safety Data |
|
|
Other Product
- (5β,9R,10α)-15,16-Epoxylabda-8(17),13(16),14-trien-19-oic acid
- 1/C15H13NO/c1-2-16-14-6-4-3-5-12(14)13-9-11(10-17)7-8-15(13)16/h3-10H,2H2,1H
- 8α-Hydroxylabda-13(16),14-dien
-19-yl p-hydroxycinnaMate
- 1/C11H9N5O/c1-17-6-2-3-8-9(4-6)16-11(14-8)7(5-12)10(13)15-16/h2-4,14H,1H3,(H2,13,15
- dynorphin A (1-13), Tyr(14)-Leu(15)-Phe(16)-Asn(17)-Gly(18)-Pro(19)-
- 1/C22H28O6/c1-23-17-11-21(27-5)19(25-3)9-15(17)13-7-8-14(13)16-10-20(26-4)22(28-6)12-18(16)24-2/h9-14H,7-8H2,1-6H3/t13-,14
- 1/C15H18N2O/c18-15-12-7-3-2-6-11(12)14-16-13-8-4-1-5-10(13)9-17(14)15/h2-3,6-7,10,13-14,16H,1,4-5,8-9H2/t10-,13-,14-/m1/s
- 1/C15H18O2/c1-11(16)6-7-12-4-3-5-13-10-14(17-2)8-9-15(12)13/h4,8-10H,3,5-7H2,1-2H
- 1/C15H22O2/c1-10(2)6-5-7-11(3)13-9-14(16)12(4)8-15(13)17/h6,8-9,11,16-17H,5,7H2,1-4H
- 1/C11H14N2O6/c1-17-7(14)4-12-2-3-13-9(10(12)15)8-6(19-13)5-18-11(8)16/h6,8-9H,2-5H2,1H
- 1/C14H19NO2/c1-3-12-10-17-9-8-15(12)14-7-5-4-6-13(14)11(2)16/h4-7,12H,3,8-10H2,1-2H
- 1/C15H22O3/c1-9-10(2)14-12(11(3)13(9)17)5-6-15(4,18-14)7-8-16/h16-17H,5-8H2,1-4H
- 1/C21H26N2O4/c1-3-14-8-9-19(25)23(12-14)11-10-16-15-6-4-5-7-18(15)22-20(16)17(13-24)21(26)27-2/h4-7,12,17,22,24H,3,8-11,13H2,1-2H
- 1/C17H22N6/c1-2-8-19-13-11-14(23-10-9-18-12-23)20-16-15(13)21-17(22-16)6-4-3-5-7-17/h9-12,19H,2-8H2,1H
- [5α,9α,10β,(+)]-Kaur-16-ene
- 1/C18H19NO4/c1-22-15-8-11-10(7-13(15)20)5-12-16-9(3-4-19-12)6-14(21)18(23-2)17(11)16/h6-8,12,19-21H,3-5H2,1-2H
- Estra-1,3,5(10)-trien-17-one,16-chloro-15-hydroxy-3-methoxy-, oxime, (15b,16a)- (9CI)
- 3α-Hydroxy-4β-hydroxymethyl-4,8-dimethyl-18-nor-16-oxa-5α-androsta-13(17),14-dien-2-one
- (5α,8β,9α,10β,13S)-13-Methyl-17-norkaur-15-en-19-oic acid
- 1/C18H30O4/c1-4-5-6-7-15(19)13-16(20)10-8-14-9-11-17(21-2)18(12-14)22-3/h9,11-12,15-16,19-20H,4-8,10,13H2,1-3H3/t15-,16-/m0/s